ER-100 treatment for open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human Phase 1 trial gives a single dose of ER-100, an AAV-based delivery of OSK proteins, to adults with open-angle glaucoma or NAION to test safety and tolerability. Systemic doxycycline is given for eight weeks to activate OSK expression and participants undergo detailed eye exams, laboratory testing, and body fluid sampling (tears, saliva, feces, urine). The study enrolls a dose-escalation cohort in OAG followed by a dose-expansion cohort in NAION and includes patient-reported quality-of-life questionnaires. Participants are followed for up to five years to monitor short- and long-term safety and vision outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have clear eye structures and be able to have your pupils safely dilated so the doctor can examine the back of your eye.
* Able to understand the study and sign a consent form.
* Be between 40 and 85 years old.
* Willing and able to follow the study schedule, including all visits and tests, and speak a language for which the study materials are available.
* If a participant can become pregnant, must agree to use a condom and one highly effective form of birth control during sex for at least 4 months after receiving the study drug (ER-100).

For participants with open-angle glaucoma (OAG):

* Diagnosis of open-angle glaucoma in the study eye.
* Eye pressure must be less than 30 mmHg, measured with a standard test.
* Visual field test must show moderate to advanced vision loss (MD score between -6 and -20 dB).
* Not expected to need glaucoma surgery in the study eye within 2 months after receiving ER-100.
* Have reasonably good vision in the study eye (at least 20/80 on a standard eye chart).

For participants with NAION (non-arteritic anterior ischemic optic neuropathy):

* Had a sudden, painless loss of vision in one eye within 14 days before receiving ER-100, confirmed by a specialist. Having had NAION in the other eye is okay.
* The affected eye must show swelling of the optic nerve.
* Visual field test must show vision loss consistent with optic nerve damage (MD worse than -3.0 dB).
* If only one eye is affected, there must be a difference in pupil response between the two eyes.
* Have vision in the affected eye between 20/40 and 2/500 on a standard eye chart.

Exclusion Criteria:

* History of optic neuritis (inflammation of the optic nerve) or repeated episodes of eye inflammation (uveitis) not caused by injury or surgery.
* Allergic reactions to tetracycline antibiotics or steroid medications.
* Moderate to severe cataracts, macular problems, or corneal issues that could interfere with eye testing.
* Unable to keep your eyes focused on a target during testing.
* Had cataract surgery or other eye surgery (including laser procedures) within 3 months before receiving the study drug.
* Had cancer (except for basal cell skin cancer) within the past 5 years.
* Have Type 1 diabetes, or poorly controlled Type 2 diabetes (A1c greater than 7 despite treatment).
* Have memory or thinking problems that prevent you from understanding the study or completing the required tests.
* Pregnant or breastfeeding.
* Have a weakened immune system, including a history of organ transplant, or test positive for HIV, hepatitis B or C, or tuberculosis.
* Have any other condition that, in the opinion of the study doctor, could increase your risk from the study drug or procedures, affect the study results, or make it hard for you to complete the study.
* Have macular disease, advanced diabetic eye disease, or other eye conditions that limit vision in the study eye.
* Eye pressure at screening is 30 mmHg or higher.
* Taking certain medications (warfarin, dilantin, carbamazepine, or barbiturates) within 14 days before starting the study or during the first 8 weeks.
* Have any other eye or vision problem that, in the opinion of the study doctor, could affect safety or interfere with vision testing.
* Have previously received any gene therapy using adeno-associated virus (AAV).

Additional Exclusion Criteria for Participants with Open-Angle Glaucoma (OAG):

\- Diagnosed with glaucoma before age 40.

Additional Exclusion Criteria for Participants with NAION:

* Show signs of giant cell arteritis (a type of blood vessel inflammation), based on abnormal blood tests.
* Had NAION start in both eyes at the same time.

Where it's running

• Global Research Management, Inc.
  Glendale, California, United States Recruiting
• Mass Eye and Ear
  Boston, Massachusetts, United States Recruiting
• Columbia University Irving Medical Center/Edward S. Harkness Eye Institute
  New York, New York, United States Recruiting
• Charleston Neuroscience Institute
  Charleston, South Carolina, United States Recruiting

Study contacts

• Study coordinator: Life Biosciences
• Email: ER100trial@lifebiosciences.com
• Phone: (857) 400-9245

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma

  In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.

  Recruiting Phase 4 Indiana University · Bloomington, Indiana · NCT07847073

• iDose TR implant administration in an office-based eye clinic

  This study tests a travoprost implant (iDose TR) given inside the eye to people with open-angle glaucoma or high eye pressure in an office setting to see if it is safe.

  Recruiting Glaukos Corporation · Austin, Texas · NCT07816692

• Brillouin hydration mapping to study cornea health

  Researchers test a Brillouin microscope to see if it can measure corneal water content in healthy people and those with eye conditions.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07780890

• Direct (non-contact) laser versus standard selective laser for treating glaucoma

  This test compares a newer non-contact laser (DSLT) with the standard SLT to see if it lowers eye pressure just as well in adults with open-angle glaucoma or ocular hypertension.

  Recruiting Medical University of South Carolina · Charleston, South Carolina · NCT07408154

• Updated inserter for the 75 mcg Travoprost intracameral implant

  This study will see if the new G2-TRIO inserter reliably and safely delivers the 75 mcg Travoprost intracameral implant in adults with open-angle glaucoma or ocular hypertension.

  Recruiting Glaukos Corporation · Kenosha, Wisconsin · NCT07400926

• Cataract surgery with iStent inject versus Kahook Dual Blade goniotomy for open-angle glaucoma

  This trial tests whether adding either two iStent inject implants or a Kahook Dual Blade goniotomy at the time of cataract surgery helps people with open-angle glaucoma lower eye pressure or reduce glaucoma medications.

  Recruiting at 2 sites Medical University of Bialystok · Bialystok, Polska and 1 other locations · NCT07325552

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.